Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s 2020 Device Budget Would Focus On Safety, Cybersecurity, Bringing Medtech 'Home'

Executive Summary

US FDA intends to use device-center dollars in its fiscal year 2020 budget on medical product safety, bolstering cybersecurity, device oversight modernization, and an initiative called “Bring Medtech Manufacturing Home,” among other priorities.

You may also be interested in...



Hacking The Budget: US FDA Asks For More Money To Tackle Cybersecurity

The agency is again trying to get extra funding in its budget for a cybersecurity information sharing portal in its proposed fiscal year 2020 budget. FDA says the approach will not only help mitigate cybersecurity risks in near-real time, but also help speed up device reviews.

US FDA Proposes Biggest Mammography Rule Change In 20 Years

US FDA wants to make significant changes to how mammographers interact with patients in terms of the information they share about the procedure and standards they will have to follow. The issue specifically addresses scenarios where patients with denser breast tissue may not be fully informed about the accuracy of their mammography tests. If the agency's proposal moves forward, it will be the biggest regulatory change for the mammography industry in more than two decades.

President Calls For Almost $100M More In Funding For FDA Device Activities In 2020

The current administration would use an additional $98m in congressional budget authority in the 2020 fiscal year for FDA’s medical device efforts to modernize its regulatory approach for technology development, to enable device safety issues to be monitored more closely, and to advance new approaches for regulating digital health technologies and breakthrough devices.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124861

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel